Login / Signup

MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

Enrica VescarelliGiulia GeriniFrancesca MegiorniEleni AnastasiadouPaola PontecorviLuciana SolitoClaudia De VitisSimona CameroClaudia MarchettiRita ManciniPierluigi Benedetti PaniciCarlo DominiciFerdinando RomanoAntonio AngeloniCinzia MarcheseSimona Ceccarelli
Published in: Journal of experimental & clinical cancer research : CR (2020)
These data demonstrate that miR-200c significantly enhanced the anti-cancer efficacy of Olaparib in drug-resistant OC cells. Thus, the combination of Olaparib with miRNA-based therapy may represent a promising treatment for drug resistant OC, and our data may help in designing novel precision medicine trials for optimizing the clinical use of PARPi.
Keyphrases